These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30983453)

  • 21. Emerging drugs in Europe.
    Papaseit E; Farré M; Schifano F; Torrens M
    Curr Opin Psychiatry; 2014 Jul; 27(4):243-50. PubMed ID: 24840157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring ecstasy content in France: results from the National Surveillance System 1999-2004.
    Giraudon I; Bello PY
    Subst Use Misuse; 2007; 42(10):1567-78. PubMed ID: 17918027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
    Van Hout MC; Hearne E
    Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decline in new psychoactive substance use disorders following legislation targeting headshops: Evidence from national addiction treatment data.
    Smyth BP; Lyons S; Cullen W
    Drug Alcohol Rev; 2017 Sep; 36(5):609-617. PubMed ID: 28419577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug abuse monitoring: which pharmacoepidemiological resources at the European level?
    Lapeyre-Mestre M; Dupui M
    Therapie; 2015; 70(2):147-65. PubMed ID: 25858571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diverse reasons for using Novel Psychoactive Substances - A qualitative study of the users' own perspectives.
    Soussan C; Andersson M; Kjellgren A
    Int J Drug Policy; 2018 Feb; 52():71-78. PubMed ID: 29241144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An early warning system for emerging drugs of concern in the emergency department: Protocol for the Western Australian Illicit Substance Evaluation (WISE) study.
    McCutcheon D; Raghavan M; Soderstrom J; Oosthuizen F; Douglas B; MacDonald E; Fatovich D
    Emerg Med Australas; 2019 Jun; 31(3):411-416. PubMed ID: 30318770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medication compliance behavior in psychiatric out-patients with psychoactive substance use comorbidity in a Nigerian tertiary hospital.
    Okpataku CI; Kwanashie HO; Ejiofor JI; Olisah VO
    Niger J Clin Pract; 2015; 18(3):371-6. PubMed ID: 25772921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns and correlates of new psychoactive substance use in a sample of Australian high school students.
    Champion KE; Teesson M; Newton NC
    Drug Alcohol Rev; 2016 May; 35(3):338-44. PubMed ID: 26194894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the toxicological significance of new psychoactive substances in fatalities.
    Elliott S; Sedefov R; Evans-Brown M
    Drug Test Anal; 2018 Jan; 10(1):120-126. PubMed ID: 28635164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Barriers to community-based drug dependence treatment: implications for police roles, collaborations and performance indicators.
    Ma Y; Du C; Cai T; Han Q; Yuan H; Luo T; Ren G; Mburu G; Wang B; Golichenko O; Zhang C
    J Int AIDS Soc; 2016; 19(4 Suppl 3):20879. PubMed ID: 27435714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health and Social Care workers' perceptions of NPS use in Northern Ireland.
    Campbell A; O Neill N; Higgins K
    Int J Drug Policy; 2017 Feb; 40():93-101. PubMed ID: 27939297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of Google Trends to monitor new psychoactive substance. Is there an added value?
    Batistic FK; Rhumorbarbe D; Lefrancois E; Tettey J; Raithelhuber M; Rossy Q; Morelato M
    Forensic Sci Int; 2021 Jul; 326():110918. PubMed ID: 34325112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of psychoactive substance use among commercial motorcyclists and its health and social consequences in Zaria, Nigeria.
    Alti-Muazu M; Aliyu AA
    Ann Afr Med; 2008 Jun; 7(2):67-71. PubMed ID: 19143162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the 'added value' of European policy on new psychoactive substances.
    Chatwin C
    Int J Drug Policy; 2017 Feb; 40():111-116. PubMed ID: 27956185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Psychoactive Substances (NPS) - the Hydra monster of recreational drugs.
    Helander A; Bäckberg M
    Clin Toxicol (Phila); 2017 Jan; 55(1):1-3. PubMed ID: 27549399
    [No Abstract]   [Full Text] [Related]  

  • 37. [Psychoactive substance use during pregnancy: a review].
    Lamy S; Thibaut F
    Encephale; 2010 Feb; 36(1):33-8. PubMed ID: 20159194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances.
    Matthews A; Sutherland R; Peacock A; Van Buskirk J; Whittaker E; Burns L; Bruno R
    Int J Drug Policy; 2017 Feb; 40():44-49. PubMed ID: 27939599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel psychoactive substances as a novel challenge for health professionals: results from an Italian survey.
    Simonato P; Corazza O; Santonastaso P; Corkery J; Deluca P; Davey Z; Blaszko U; Schifano F
    Hum Psychopharmacol; 2013 Jul; 28(4):324-31. PubMed ID: 23881880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A critical examination of the definition of 'psychoactive effect' in Australian drug legislation.
    Barratt MJ; Seear K; Lancaster K
    Int J Drug Policy; 2017 Feb; 40():16-25. PubMed ID: 27884504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.